Physician profile
Marissa Cvelbar
NPI 1841877727
$2,663.73
in general payments reported to CMS, 2019-2025
34 companies · $59.07 in 2025
The $59.07 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $1,311 · 2023: $490 · 2024: $681 · 2025: $59.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.99 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $244.16 | 2024 | Veozah |
| Exeltis, USA INC. | $192.33 | 2023-2024 | Slynd |
| Idorsia Pharmaceuticals US INC | $191.40 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $183.70 | 2021-2022 | |
| Alkermes, INC. | $174.39 | 2022-2023 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.59 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $160.39 | 2022 | |
| Abbvie INC. | $150.17 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $144.93 | 2023-2024 | Myfembree, Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $127.96 | 2021-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $89.62 | 2022-2023 | Qelbree |
| Sage Therapeutics, LLC | $85.90 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $74.96 | 2022-2023 | Austedo |
| Almatica Pharma LLC | $70.94 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $63.03 | 2022-2023 | Ingrezza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $48.83 | 2023 | |
| Bausch Health US, LLC | $48.42 | 2022-2023 | Aplenzin |
| Merck Sharp & Dohme LLC | $40.38 | 2022-2024 | Gardasil 9, Gardasil |
| Neos Therapeutics, LP | $39.60 | 2022-2023 | Adzenys Xr-Odt |
| Becton, Dickinson and Company | $36.88 | 2024 | Arista Ah Flexitip |
| Bayer Healthcare Pharmaceuticals INC. | $34.99 | 2023-2025 | |
| Tris Pharma INC | $30.87 | 2022-2023 | Dyanavel Xr |
| Coopersurgical, INC. | $30.04 | 2025 | Paragard T 380a |
| Lundbeck LLC | $29.94 | 2022 | |
| Organon LLC | $29.63 | 2024-2025 | Nexplanon |
| Noven Therapeutics, LLC | $24.47 | 2023 | Secuado |
| Axsome Therapeutics, INC. | $21.62 | 2022 | |
| Corium, LLC | $21.47 | 2023 | Azstarys |
| Pfizer INC. | $19.45 | 2024 | |
| Sanofi Pasteur INC. | $17.99 | 2024 | |
| Adlon Therapeutics L.P. | $17.78 | 2021 | |
| Daiichi Sankyo INC. | $17.47 | 2023 | Injectafer |
| Convatec INC. | $17.17 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $16.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Cvelbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.